Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
60 participants
INTERVENTIONAL
2023-08-30
2025-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants are randomly assigned to one of the two treatments. Treatment consists of 3 sessions. Participants receiving the standard treatment (i.e., sleep hygiene and episode risk reduction) may subsequently receive medical hypnosis.
Participation in the study involves 5 visits in total: 3 treatment visits and 2 study visits to the hospital (CHUV).
* An initial study visit to provide information and collect questionnaires prior to the start of treatment. An initial non-therapeutic hypnosis session will be carried out during electroencephalography. Estimated duration: 2h.
* A second study visit at the end of treatment, including questionnaires about your sleep and treatment. A shorter non-therapeutic hypnosis session and a second electroencephalography will be performed. Estimated duration: 1h30. This visit may also be followed by an overnight polysomnography, according to patient's choice (if performed, estimated total duration 12 hrs).
This study also involves monitoring patients' sleep for 10 nights before and after treatment: they will fill in a sleep diary and use an infrared camera.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Non-pharmacological Treatment of Insomnia in Nursing Homes.
NCT01091987
Brief Intervention for Sleep Medication Misuse Among Elderly
NCT06032715
Telepsychology for Benzodiazepines Withdrawal in Adults Suffering From Hypnotic-dependent Insomnia
NCT04751851
i-Sleep: Internet-based Treatment for Insomnia
NCT03110263
An Investigational Study to Assess Efficacy and Pattern of Use of SM-1 in Subjects With a History of Transient Insomnia
NCT03338764
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Medical hypnosis (HYP)
3 medical hypnosis interventions
Medical hypnosis
Hypnosis intervention with specific suggestions (i.e., patient's own dreamlike mentation)
Standard Of Care (SOC)
3 standard of care quality and sleep safety interventions
Standard Of Care
Sleep hygiene and safety education session
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Medical hypnosis
Hypnosis intervention with specific suggestions (i.e., patient's own dreamlike mentation)
Standard Of Care
Sleep hygiene and safety education session
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willling and able to give informed consent
* Reporting at least one parasomniac episode per month
* Reporting at least one parasomniac episode the month prior
Exclusion Criteria
* Current or planned intake (during the next 2 months) of medications/substances that may interfere with sleep architecture (e.g., hypnotics, neuroleptics, antidepressants, benzodiazepines)
* A comorbid significant somatic disease altering the brain (e.g., cancer, epilepsy, multiple sclerosis, dementia)
* A comorbid sleep disorder (e.g., apnea-hypopnea index (AHI) \>= 20/hour, REM sleep behaviour disorder, restless legs syndrome with symptoms more than 2 days/week)
* A comorbid psychiatric disorder (e.g., severe depressive or anxiety disorder or psychotic disorder)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Lausanne Hospitals
OTHER
Chantal Berna Renella
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chantal Berna Renella
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chantal Berna Renella, Prof
Role: PRINCIPAL_INVESTIGATOR
CHUV
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre hospitalier universitaire vaudois (CHUV)
Lausanne, Canton of Vaud, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CER-VD 2023-01007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.